Skip to content

CorMedix CRMD Cash received from option exercises

Cash received from option exercises at other companies

Haemonetics logo
HaemoneticsHAE

Other financials

Income statement

See full
Revenue$127.4M+226%
Gross profit$115.4M+207%
Operating income$63.7M+216%
Net income$38.6M+87.0%
EPS (diluted)$0.43+43.3%

Balance sheet

See full
Cash & equivalents$179.1M+170%
Total debt$4.3M+729%
Total equity$437.0M+280%
Total assets$815.6M+445%

Cash flow

See full
Operating cash flow$42.4M+115%
CapEx$729.0K+7,190%
Free cash flow$41.7M+111%

Valuation

See full
Market cap$605.65M-34.4%
P/E3.4×
P/S1.5×-9.6×

Profitability

See full
Gross margin91.9%-3.5pp
Operating margin48.4%
Net margin45.2%
FCF margin48.7%+38.8pp

Returns & leverage

See full
Return on equity65.6%
Debt / equity0.0×
Current ratio-1.2×

Where this comes from

Reported directly by CorMedix in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromStockOptionsExercised.

The official record: CorMedix’s 10-Q, filed May 14, 2026, on SEC EDGAR. View the filing →

Ask your AI about CorMedix's cash received from option exercises.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is CorMedix's cash received from option exercises?
CorMedix (CRMD) reported cash received from option exercises of $1.18M in Q1 2026.
How has CorMedix's cash received from option exercises changed year-over-year?
CorMedix's cash received from option exercises increased by 236.5% year-over-year, from $350.35K to $1.18M.
What does cash received from option exercises mean?
Reflects cash inflows received from employees or directors exercising their vested stock options. It serves as a measure of the cash generated from internal incentive programs and the realization of employee equity value.